Literature DB >> 12829029

Chemotherapy prior to autologous bone marrow transplantation impairs long-term engraftment in mice.

Estelle J K Noach1, Albertina Ausema, Ronald van Os, Imre Akkerman, Sonja Koopal, Ellen Weersing, Bert Dontje, Edo Vellenga, Gerald de Haan.   

Abstract

OBJECTIVE: Autologous bone marrow transplantation in cancer patients is often preceded by multiple cycles of chemotherapy. In this study, we assessed in a mouse model whether stem cells were affected by prior chemotherapy.
METHODS: Donor mice were treated with three consecutive injections of 150 mg/kg 5-fluorouracil (5-FU). Peripheral blood counts were allowed to recover before the subsequent dose of 5-FU was given. Mice recovered from three doses of 5-FU and showed normal steady-state hematopoiesis. Bone marrow cells from these mice were mixed with congenic competitor cells and transplanted into lethally irradiated recipients.
RESULTS: Although in vivo homing of cells from these mice was not impaired, donor leukocyte contribution steadily decreased posttransplantation. In contrast to in vivo homing, both in vitro migration toward stromal-derived factor (SDF)-1 and the average CXC chemokine receptor-4 (CXCR4) expression were lower in 5-FU-treated cells. Moderate reductions in L-selectin and CD11a expression were observed on stem cells of 5-FU-treated mice. CD43, CD44, CD49d, and CD49e were normally expressed and could thus not explain the reduced engraftment of these cells.
CONCLUSION: We therefore conclude that 5-FU either directly damages stem cells or that the replicative stress induced by 5-FU causes a decline in stem cell reconstitution potential resulting in lower chimerism levels posttransplantation, that declines in time.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829029     DOI: 10.1016/s0301-472x(03)00068-7

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  7 in total

1.  Neuropeptide Y regulates the hematopoietic stem cell microenvironment and prevents nerve injury in the bone marrow.

Authors:  Min Hee Park; Hee Kyung Jin; Woo-Kie Min; Won Woo Lee; Jeong Eun Lee; Haruhiko Akiyama; Herbert Herzog; Grigori N Enikolopov; Edward H Schuchman; Jae-sung Bae
Journal:  EMBO J       Date:  2015-04-27       Impact factor: 11.598

2.  Variant rs1801157 in the 3'UTR of SDF-1ß does not explain variability of healthy-donor G-CSF responsiveness.

Authors:  Miriam Schulz; Darja Karpova; Gabriele Spohn; Annette Damert; Erhard Seifried; Vera Binder; Halvard Bönig
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

3.  Neuropeptide Y improves cisplatin-induced bone marrow dysfunction without blocking chemotherapeutic efficacy in a cancer mouse model.

Authors:  Min Hee Park; In Kyung Jung; Woo-Kie Min; Jin Ho Choi; Gyu Man Kim; Hee Kyung Jin; Jae-Sung Bae
Journal:  BMB Rep       Date:  2017-08       Impact factor: 4.778

4.  Fecal microbiota transplantation reverses antibiotic and chemotherapy-induced gut dysbiosis in mice.

Authors:  Quentin Le Bastard; Tonya Ward; Dimitri Sidiropoulos; Benjamin M Hillmann; Chan Lan Chun; Michael J Sadowsky; Dan Knights; Emmanuel Montassier
Journal:  Sci Rep       Date:  2018-04-18       Impact factor: 4.379

5.  Novel peptides derived from neuropeptide Y prevent chemotherapy-induced bone marrow damage by regulating hematopoietic stem cell microenvironment.

Authors:  Min Hee Park; Bosung Baek; Hee Kyung Jin; Jae-Sung Bae
Journal:  Anim Cells Syst (Seoul)       Date:  2018-09-05       Impact factor: 1.815

6.  Apelin+ Endothelial Niche Cells Control Hematopoiesis and Mediate Vascular Regeneration after Myeloablative Injury.

Authors:  Qi Chen; Yang Liu; Hyun-Woo Jeong; Martin Stehling; Van Vuong Dinh; Bin Zhou; Ralf H Adams
Journal:  Cell Stem Cell       Date:  2019-11-21       Impact factor: 24.633

7.  Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration.

Authors:  Daniel Lucas; Christoph Scheiermann; Andrew Chow; Yuya Kunisaki; Ingmar Bruns; Colleen Barrick; Lino Tessarollo; Paul S Frenette
Journal:  Nat Med       Date:  2013-05-05       Impact factor: 53.440

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.